For this reason, it can be difficult for patients and healthcare providers alike to discern whether the medication is working as intended or the person has had a relapse into disordered eating, says Brad Smith, MD, a physician in Madison, Wisconsin, and the chief medical officer for the Emily Program, a network of eating disorder treatment centers
A sharp peak followed by return to baseline within 90120 minutes
Medications in this category, including semaglutide and tirzepatide , affect appetite regulation and food intake
The question, as with combining GLP-1 and GIP receptor activity, is whether adding glucagon receptor activity to GLP-1 receptor activity exceeds the glycaemic lowering and weight loss achieved with a GLP-1 RA alone (Ambury et al, 2018